Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 93

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 93
---

these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review
the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See “Where
You Can Find More Information.”

<div align='center'>57

USE OF PROCEEDS</div>

We expect to receive approximately
$ million in net proceeds from the sale of Ordinary Shares offered by us in this offering (approximately
$ million if the Representative’s exercises its over-allotment option in full), based upon an
assumed public offering price of $ per Ordinary Share, which is the midpoint of the price range set forth
on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable
by us.

Each $0.25 increase or decrease
in the assumed initial public offering price of $ per Ordinary Share, which is the midpoint of the price
range set forth on the cover page of this prospectus, would increase (decrease), the net proceeds to us from this offering by $ million,
assuming the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Ordinary
Shares we are offering. An increase (decrease) of in the number of Ordinary Shares offered by
us would increase (decrease) the net proceeds to us from this offering by $ million, assuming no change
in the assumed initial public offering price and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $     million for development activities and preparation of the PMA submission for GelrinC; |

| ● | approximately $      million                                      
 to complete the pivotal trial for GelrinC and related activities; |

| ● | approximately                                                      
 $     for the repayment of the Bridge Loan (as defined below); and |

| ● | the remainder for working capital and general corporate purposes and possible future acquisitions. |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is
necessary. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult